摘要
目的评价奥氮平与利培酮治疗首发精神分裂症的临床疗效及安全性。方法将符合入组标准的首发精神分裂症患者96例随机分为奥氮平组与利培酮组,分别治疗8周。采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效及副反应。结果奥氮平组与利培酮组的总有效率分别为91.67%和89.36%,差异无统计学意义(P>0.05);两组治疗前后PANSS评分比较差异均无统计学意义(P>0.05)。两组治疗中的不良反应发生率低、程度轻,奥氮平组体重增加比例高于利培酮组,利培酮组锥体外系反应比例高于奥氮平组。结论奥氮平与利培酮治疗首发精神分裂症疗效相当,不良反应轻,但不良反应有异同。奥氮平组体重增加较多,利培酮组锥体外系反应发生较多。两种药物均为疗效好、安全性高的抗精神病药。
Objective To evuluate the clinical efficacy and safety of olanzapine and risperidone in the treatment of first-episode schizophrenia. Methods 96 patients with diagnosis of first episode schizo phrenia were randomly assigned to two groups that were treated with olanzapine and risperidone respectively for 8 weeks. The therapeutic response and side effects were evaluated with PANSS and TESS. ResultsThe overall effective rate of olanzapine and risperidone were 91. 67% and 89.36% respectively（P〈0.05）. There were no significant differences in PANSS scores between the two groups （P〈0.05）. During the treatment, the two groups effects were less and milder. Olanzapine was associated with more weight gain and risperidone with more EPS（extrapyramidal syndrome）. Conclusion the results suggest that olanzapine is as effective as risperidone for the treatment of first-onset schizophrenia and fewer side effects in them, although there are different or the same side effects in two drugs. Olanzapine is associated with more weight gain and risperidone with more EPS. The two drugs are efficacy and safety antipsychotic drugs in treatment of first-episode schizophrenia.
出处
《贵州医药》
CAS
2010年第3期221-223,共3页
Guizhou Medical Journal
关键词
奥氮平
利培酮
首发精神分裂症
Olanzapine Risperidone First-episode schizophrenia
